Introduction
============

Sodium iodide symporter is a transmembrane glycoprotein (codified by the *SLC5A5* gene) expressed almost exclusively in the basolateral plasma membrane of thyroid follicular cells. It plays a central role in thyroid metabolism, mediating the active transport of iodine from the bloodstream into the follicular cells, the first step for thyroid hormones' synthesis. NIS plays an essential role in the treatment of differentiated thyroid carcinomas (DTC), which usually maintain NIS expression, allowing the recognition and the treatment of recurrences and metastases with radioactive iodine (RAI) ([@bib1]). Nonetheless, a significant subgroup of DTC patients with advanced disease lose NIS expression and become refractory to ^131^I; some of these patients die within 3--5 years ([@bib2]). Furthermore, a study performed by Yildririm-Poyraz and coworkers ([@bib3]) demonstrated that NIS expression in nontumoral thyroid tissues associates with higher rates of delayed structural response. NIS expression has been widely studied in normal thyroid and tumor tissues, on one hand to verify if its downregulation could be the molecular cause for the decrease of RAI uptake and on the other hand to understand the impairing mechanisms of NIS expression and function. However, no clear answer emerged from the results obtained in the previous studies. Despite the central role of NIS in diagnosis, treatment and follow-up of thyroid cancer patients, reliable methods for ascertaining NIS expression and functionality in clinical samples are not available.

In the majority of the studies, *SLC5A5* mRNA levels are lower in thyroid carcinomas than in adenomas ([@bib4]) and normal adjacent thyroid ([@bib5], [@bib6], [@bib7]); furthermore, *SLC5A5* expression presents some limitations in predicting NIS expression and functionality: whereas a negative or low mRNA level may lead to reduced protein expression, a positive or high mRNA expression does not always correspond to higher protein levels or higher functionality ([@bib7], [@bib8]).

These observations suggest that in thyroid carcinomas, besides transcription regulation, NIS expression appears to be modulated by post-transcriptional events. Therefore, studies of NIS expression by immunohistochemistry (IHC) ([@bib1], [@bib9], [@bib10], [@bib1], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib9], [@bib20], [@bib1], [@bib22], [@bib23], [@bib24], [@bib25]), may be, theoretically, more informative since they 'grab' NIS a step forward in its biological processing and allow the evaluation of the localization of NIS in the basolateral plasma membrane of follicular cells (the functional transporter).

According to the published data, NIS expression (evaluated by IHC) varies in different thyroid tissues. In normal thyroid, it is low and very heterogeneous; only a few follicular cells within some follicles express NIS in the basolateral plasma membrane ([@bib10], [@bib14], [@bib17], [@bib21], [@bib26]), suggesting that, NIS expression is tightly regulated in thyroid gland. In carcinomas, when NIS is present, it is usually expressed in a higher number of cells than in normal tissue and the expression is mainly intracytoplasmic, poorly targeted to the basolateral plasma membrane ([@bib1], [@bib1], [@bib12], [@bib13], [@bib14], [@bib17], [@bib1], [@bib22], [@bib23]). The increased intracytoplasmic NIS staining in thyroid tumors compared to normal tissue has been pointed out as a reason for the decreased RAI uptake in tumors, reflecting a mislocalization of NIS from the basolateral membrane, which would impair its activity ([@bib17]). This assumption has been questioned, because the real significance of intracytoplasmic NIS detected by immunostaining remains unclarified ([@bib21]).

The molecular mechanisms responsible for the downregulation and/or not targeting to the basolateral membrane of NIS in thyroid tumors remain poorly understood, but some studies demonstrated that both mRNA and protein are differentially expressed according to the genetic background of the tumor. In fact, papillary thyroid carcinomas (PTCs) harboring the *BRAF*V600E mutation present lower *SLC5A5* mRNA and NIS protein expression as well as less targeting to the basolateral membrane compared to PTCs *BRAF*WT ([@bib19], [@bib24], [@bib27]). Nonetheless, a recent study reported different association between NIS membrane expression and *BRAF*V600E mutation in a series of 96 cPTCs, demonstrating that the ones harboring *BRAF*V600E mutation expressed more often NIS in the cell membrane of tumor cells compared to *BRAF*WT cPTCs ([@bib28]). Less is known about the impact of mutations in other genes (i.e. *RAS* and *TERT*p) on *SLC5A5* and NIS expression/targeting to the basolateral membrane.

NIS being the central molecule for DTC treatment, it is logical to study if its expression in the primary tumor would be helpful in predicting therapy response as well as tumor behavior and prognosis. Some studies tried to understand if NIS immunohistochemical expression in thyroid primary tumors would be helpful in predicting ^131^I uptake in recurrences and distant metastases. Although positive NIS immunostaining in primary tumors seemed to be predictive of positive recurrences and metastases on ^131^I scans, other studies did not distinguish whether NIS was expressed in the cell basolateral membrane, and negative NIS staining did not predict ^131^I scan-negative metastases ([@bib13], [@bib15], [@bib18]). Even when only NIS membrane staining was considered, a negative NIS staining in the primary tumor was still not predictive of a negative ^131^scan of subsequent recurrences ([@bib29]). To the best of our knowledge, there is only one study that addressed possible associations between NIS expression, evaluated by immunohistochemistry (IHC), and clinicopathological features and prognosis in a large series of thyroid primary tumors ([@bib1]), reporting a significantly lower NIS expression in older patients (≥45 years) and also that NIS expression in the primary tumor was not useful as a prognostic marker.

So, in our opinion, more retrospective studies in larger series of primary tumors are still necessary, to understand the role of NIS expression in therapy response, tumor behavior and prognosis, and also if other factors besides *BRAF*V600E mutation can contribute to NIS downregulation and/or misdirecting to the basolateral membrane. Furthermore, it is also important to understand the advantages and limitations of the analysis of *SLC5A5* and NIS expression and evaluate what is the better/more informative method to study NIS expression.

Having this in mind, we addressed *SLC5A5* expression by qPCR and NIS expression by IHC analysis, in a large series of primary thyroid carcinomas and looked for possible associations with some clinicopathological and molecular features, as well as to the response to RAI therapy and outcome. In order to validate our results of *SLC5A5* mRNA expression associations' with clinicopathological and molecular features and also to get new evidences, we used the data available about *SLC5A5* in TCGA Research Network that completed an integrated genomic analysis of 496 PTCs using NGS and other pan-genomic technologies, together with detailed pathologic and clinical data ([@bib30]).

Materials and methods
=====================

Patient samples
---------------

Our series was composed by 255 thyroid samples from 229 patients. Cases were collected from the files of the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP, Porto, Portugal), corresponding to patients with thyroid tumors (*n* = 229) operated and followed in two university hospitals. Samples from normal thyroid (*n* = 25) and Graves' disease (*n* = 1) were obtained from the contralateral lobe of the surgical specimens. Carcinomas series was composed by 193 PTCs (123 cases of classical PTC (cPTC), 47 cases of follicular variant of PTC (fvPTC) and 23 cases of other PTC variants), 23 follicular thyroid carcinomas (FTC) and 13 poorly differentiated thyroid carcinomas (PDTC). In 166 of the cases, there was only formalin-fixed paraffin-embedded (FFPE) representative tissue; in 45 cases, there were FFPE samples and correspondent frozen tissue (the tumors were divided at the time of surgery) and in 18 cases, there was only frozen tissue available. Frozen material was collected at the time of surgery and conserved at −80°C. The histology of all tumor samples was reviewed by three pathologists (CE, ER, MSS) according to the criteria of the World Health Organization ([@bib31]). Clinicopathological and molecular data of the 229 patients with carcinoma are summarized in [Supplementary Table 1](http://www.endocrineconnections.org/cgi/content/full/EC-17-0302/DC1) (see section on [supplementary data](#supp1){ref-type="supplementary-material"} given at the end of this article). In 141 cases, follow-up data were available. The number of ^131^I treatments varied from 1 to 5 treatments (mean 1.9), and the cumulative total dose of RAI was between 30 and 1146 mCi (mean 251 mCi). This work was approved by the Ethic Committee for Health (CES) of the Hospital Center of São João (CHSJ)/Faculty of Medicine of the University of Porto (FMUP) (CES 137 284--13) and by the Ethic Committee of the Faculty of Medicine of the University of Coimbra (n° 1309). All the procedures described in this study were in accordance with national ethical standards (Law n° 12/2005) and Helsinki declaration. Patients signed an informed consent form.

Patient follow-up
-----------------

Patients were treated and followed in accordance with the international protocols available at the time. Data regarding the number of radioiodine treatments and cumulative activity were retrieved from hospital records. Patients were considered as being disease-free at the end of follow-up if they had undetectable stimulated thyroglobulin (in the absence of thyroglobulin antibodies), and no evidence of the disease on radiographic or radionuclide imaging. Follow-up time (in years) varied from 0.3 up to 38.9 years, with a mean value of 8.0 ± 6.6 years. For statistical analysis, we defined the category 'additional treatments', in which we included other treatment modalities in addition to radioiodine, including extra surgery, external beam irradiation and treatment with tyrosine kinase inhibitors.

Dataset PTC in TCGA
-------------------

There were 378 tumor cases for which there was information for the main driver somatic mutations (*TERT*p, *BRAF* and *RAS*), gender and *SLC5A5* expression. Of these, we eliminated 4 cases, for which the *SLC5A5* expression was above the 99 percentile, being outliers. A total of 353 of the cases had information about tumor size, 362 had information for extrathyroidal extension, 282 had information for lymph node metastases (at the time of diagnosis) and all 374 had information about new tumor event (lymph node metastases or local recurrence (grouped in locoregional recurrence) and distant metastases). The *SLC5A5* expression was inferred from RNA-seq data and quantification reflects reads per kilobase per million mapped reads (RPKM).

There were also 58 *SLC5A5* expression measures in adjacent tissue of the PTC cases, and two of them were not considered for further analyses as values were above the 99 percentile.

DNA extraction, PCR and Sanger sequencing
-----------------------------------------

DNA extraction from FFPE tissues was performed from 10 μm sections after careful microdissection. DNA extraction was performed using Ultraprep tissue DNA kit (AHN Biotechnologie, Nordhausen, Germany) following the manufacturer's instructions. The genetic characterization of part of the tumors regarding *BRAF*, *NRAS* and *TERT* promoter mutations (*TERT*p) had been reported previously; mutations were screened as previously described ([@bib32], [@bib33], [@bib34]).

RNA extraction and reverse transcription
----------------------------------------

Total RNA was extracted from tumors and from contralateral normal adjacent thyroid, from which frozen samples were available (*n* = 84), using a TRIzol commercial kit (Thermo Scientific/GIBCO) according to the manufacturer's protocol. RNA was quantified by spectrophotometry, and its quality was checked by analysis of 260/280 nm and 260/230 nm ratios. For cDNA preparation, 1 μg of total RNA was reverse-transcribed using the RevertAid first-strand cDNA synthesis kit (Thermo Scientific/Fermentas).

Real-time PCR
-------------

Reverse transcription products were amplified for the *SLC5A5* gene and detected by a probe (IDT: Integrated DNA Technologies, Leuven, Belgium; no. HS.PT.56a.40789288), as previously described ([@bib35]).

Immunohistochemistry
--------------------

Immunohistochemistry was performed in normal thyroid and in 211 carcinomas. Briefly, deparaffinized and rehydrated sections were subjected to heat-induced antigen retrieval in 10 mM sodium citrate buffer (pH 6.0). Endogenous peroxidase activity was blocked with 3% of hydrogen peroxide and nonspecific binding with Large Volume Ultra V Block reagent (Thermo Scientific/Lab Vision). Sections were then incubated overnight at 4°C with anti-NIS antibody (1:400) clone FP5A (Thermo Scientific/Lab Vision) and in 24 carcinomas with anti-NIS pAb 795 IgG (20 µg/mL) (kindly supplied by Dr Ruby) ([@bib36]). Additionally, Tyramide Signal Amplification (TSA) Biotin System (Perkin-Elmer) was used for signal amplification in 44 carcinomas, according to manufacturer's instructions. The detection was performed with a labeled, streptavidin--biotin immunoperoxidase detection system (Thermo Scientific/Lab Vision) followed by 3,3′-diaminobenzidine (Dako) and counterstained with hematoxylin. Graves' disease sample was used as a positive control and the negative control consisted in omission of the primary antibody.

Slides were evaluated by two observers and were analyzed according to the percentage of tumor-stained cells, the intensity and the cellular localization of the staining. In order to compare our results to the literature, we considered cases with \>5% of stained tumor cells (regardless of the cellular localization) as positive. Nevertheless, all our statistical analyses were performed considering two groups; cases that presented membrane staining in tumor cells and all the other cases. Photographs were acquired using Nikon DS-L1 camera in 100× and 400× magnifications.

Statistical analysis
--------------------

Statistical analysis was performed using 21.0 SPSS Statistical Package (SPSS, 2003). Fisher's exact test and independent-samples *t*-test were performed to correlate NIS and *SLC5A5* mRNA expression with clinicopathological and molecular features. When parametric tests were not applicable, we used alternative tests, specifically Mann--Whitney (independent samples). Wilcoxon (related samples) was used to compare *SLC5A5* expression between tumor samples and their adjacent normal counterparts. Kruskal--Wallis test was used to correlate *SLC5A5* expression (retrieved from TCGA and database) with clinicopathological and molecular features. Values of *P* ˂ 0.05 were considered statistically significant.

Results
=======

*SLC5A5* mRNA expression
------------------------

*SLC5A5* expression was significantly lower in carcinomas than that in normal adjacent counterparts ([Fig. 1](#fig1){ref-type="fig"}). No significant difference was observed between the three different carcinoma histotypes (PTC, FTC and PDTC). Considering the analysis in DTC, *SLC5A5* expression was significantly lower in males and in cases with vascular invasion (*P* = 0.003 and *P* = 0.03, respectively) ([Table 1](#tbl1){ref-type="table"}). *SLC5A5* expression in normal thyroid from males was not significantly different from that of females (data not shown). In addition, there was a tendency to lower *SLC5A5* levels in cases with extrathyroidal extension (*P* = 0.06) and in PTCs harboring *BRAF*V600E mutation (*P* = 0.07). When the statistical analysis was performed only in the PTC group, all the significant associations described in the DTC group were maintained. Figure 1*SLC5A5* mRNA expression in thyroid carcinomas and paired normal adjacent counterparts. Table 1Associations between *SLC5A5* mRNA expression with clinicopathological and molecular features in DTCs.***SLC5A5* expression*P* value**GenderF (*n* = 47)1.2 ± 2.2M (*n* = 12)0.2 ± 0.20.003Age\<45 years (*n* = 30)1.0 ± 1.5≥45 years (*n* = 29)1.1 ± 2.40.8Tumor capsulePresent (*n* = 27)1.1 ± 1.6Absent (*n* = 30)0.7 ± 1.60.4Tumor capsule invasionYes (*n* = 17)0.9 ± 1.6No (*n* = 11)1.4 ± 1.40.4Extrathyroidal extensionYes (*n* = 17)0.5 ± 1.1No (*n* = 37)1.4 ± 2.40.06Lymphocytic infiltrationPresent (*n* = 19)0.9 ± 1.9Absent (*n* = 37)1.2 ± 2.20.7Vascular invasionPresent (*n* = 28)0.4 ± 0.8Absent (*n* = 29)1.5 ± 2.60.03Lymph node metastasesPresent (*n* = 13)0.5 ± 0.8Absent (*n* = 18)0.4 ± 0.70.8*BRAF*\*WT *n* =  (27)1.6 ± 2.7V600E (*n* = 20)0.5 ± 1.00.07*NRAS*WT (*n* =  54)1.0 ± 2.0Mut (*n* =  6)1.3 ± 1.70.7[^1]

*SLC5A5* mRNA expression (TCGA database)
----------------------------------------

The *SLC5A5* expression was around 200 times higher in normal tissue than in tumor tissue in both genders, but no differences in tumor and in adjacent tissue between genders were found ([Fig. 2A](#fig2){ref-type="fig"} and [B](#fig2){ref-type="fig"}). *SLC5A5* expression was significantly higher in smaller tumors ≤2 cm (median = 5.85) compared to those with \>2 cm (median = 2.51) (*P* = 0.028; [Fig. 2C](#fig2){ref-type="fig"}). There was no statistical difference in *SLC5A5* expression in primary tumors with (median = 3.0) or without (median = 5.4) lymph node metastases at the time of diagnosis (*P* = 0.253) ([Fig. 2D](#fig2){ref-type="fig"}). Figure 2*SLC5A5* expression in primary PTCs (RPKM), data retrieved from TCGA database. Comparative analysis of *SLC5A5* expression. (A) Between genders in tumor (TT) and normal tissue (NT); (B) between genders only in tumor tissue (TT); (C) in tumors with ≤2 cm and \>2 cm; (D) in cases with or without lymph node metastases at the time of diagnosis; (E) in cases without, with minimal (T3) and with moderate/advanced extrathyroidal extension (T4a+b); (F) in cases with and without recurrence and (G) between cases with different genetic backgrounds (WT, *RAS* mutation, *TERT*p mutation, *BRAF* mutation, *BRAF* + *TERT*p mutation). The boxes represent the interquartile range; the whiskers are the 5% and 95% quartiles; the small open boxes are the mean values and the lines are the median values. Significant values for the Kruskal--Wallis test are indicated.

The *SLC5A5* expression was reduced with the level of the extrathyroidal extension (median values: 5.4 for 'none'; 2.8 for 'minimal (T3)' and 0.9 for 'moderate/advanced (T4a + b)'), reaching statistical significance for comparisons between 'none' vs the 'moderate/advanced (T4a + b)' class and 'minimal (T3)' vs 'moderate/advanced (T4a + b)' (*P* = 0.018 and *P* = 0.039, respectively [Fig. 2E](#fig2){ref-type="fig"}). We also observed a statistical significant decrease (from a median of 3.8 to 0.8; *P* = 0.002) of the *SLC5A5* expression in cases with new tumor events ([Fig. 2F](#fig2){ref-type="fig"}), lumping together 12 cases of distant metastasis (6 lung; 1 lung + bone; 1 lymph node only; 1 lung + femur + neck + pleura + liver; 1 bone; 2 unknown) and 14 locoregional recurrences (10 lymph node only; 2 left thyroid; 1 lymph node + soft tissue; 1 unknown). Finally, *SLC5A5* expression was significantly higher in the absence (median = 21.77) of the evaluated mutations: *RAS* (*P* = 0.034), *TERT*p (*P* = 0.0072) and *BRAF*V600E (*P* = 3.1 × 10^−8^). The PTCs that harbored only *TERT*p, only *BRAF* or simultaneous *TERT*p and *BRAF* mutations displayed significantly lower expression of *SLC5A5* than the WT tumors. The group with *RAS* mutations displayed the second highest expression value (median = 7.50), reaching statistical significance when compared with the groups including *BRAF* mutation only and *BRAF* + *TERT*p mutations (median = 2.27 in *BRAF* (*P* = 0.042); median = 1.89 in *TERT*+*BRAF* (*P* = 0.027)) ([Fig. 2G](#fig2){ref-type="fig"}).

NIS expression
--------------

In normal thyroid tissues, NIS immunohistochemical expression was mainly localized in the basolateral plasma membrane of follicular cells. NIS positivity was detected in a few foci of isolated follicles throughout the tissue and within the positive follicles most of the cells were positive. Positivity was more frequently detected in small follicles composed by cuboidal and columnar cells and rarely detected in large follicles limited by flattened cells ([Fig. 3A](#fig3){ref-type="fig"}). In Graves' disease, NIS was widely expressed and present in the basolateral plasma membrane of the great majority of follicular cells ([Fig. 3B](#fig3){ref-type="fig"}). In carcinomas, NIS staining was observed in 71.6% of the cases (74.8% of cPTCs, 69.8% of fvPTCs, 80.9% of other PTC variants, 55% of FTC and 67% of PDTC). Its location was predominantly in the cytoplasm (124/211) ([Fig. 3C](#fig3){ref-type="fig"}) and nucleus (15/211) and only 12/211 of the cases presented NIS in the basolateral plasma membrane of tumor cells ([Fig. 3D](#fig3){ref-type="fig"}). Figure 3NIS immunoexpression in different thyroid tissues. (A) Normal thyroid; (B) Graves' disease; (C) cytoplasmatic staining in an oncocytic PTC; (D) membrane staining in a fvPTC; (E and F) NIS immunoexpression in a fvPTC without and with TSA amplification signal, respectively; (G and H) NIS immunoexpression in a FTC without and with TSA amplification signal, respectively; (I) negative staining in a cPTC and strong membrane staining in the surrounding Graves' disease. In F and H, notice the loss of cytoplasmatic staining after the use of TSA amplification system. Bar 100 μm.

Since we observed a low percentage of carcinomas with NIS staining in the basolateral membrane, we hypothesized that our IHC approach was not being sensitive enough to detect small amounts of NIS. To clarify this issue, we used two strategies: a TSA signal amplification method and the use of another NIS antibody characterized by a different specificity compared to the commercial antibody ([@bib36]).

The TSA signal amplification method was applied in a subset of 44 carcinomas with different staining patterns (16 with cytoplasmic staining in the tumor and membrane staining in adjacent thyroid; 3 with membrane staining in the tumor; 5 negative both in the in tumor and the adjacent thyroid and, finally, 20 with only cytoplasmic staining in tumor and adjacent thyroid). When we compared the slides performed with and without TSA signal amplification, we verified that only the membrane staining remained and appeared more intense with the amplification method. In these cases, the staining involved almost always the same foci of cells that already presented membrane staining ([Fig. 3E](#fig3){ref-type="fig"}, [F](#fig3){ref-type="fig"}, [G](#fig3){ref-type="fig"} and [H](#fig3){ref-type="fig"}) i.e. it did not stain additional cells. The intra-cytoplasmic staining vanished both in cancer and in normal tissues. Furthermore, we performed IHC using a homemade antibody for human NIS, pAb 795 against a peptide corresponding to the C-terminal sequence of hNIS pAb 795 ([@bib36]) in 24 carcinomas (12 cPTC, 4 fvPTC, 2 micro PTC, 2 tall cell PTC, 2 FTC and 2 PDTC). The results were similar to those obtained with clone FP5A (Thermo Scientific/Lab Vision).

Since some doubts remained about the specificity of the cytoplasmic staining, and because NIS is only active when present in the basolateral membrane of the cells, we performed statistical analysis dividing our series in two groups: with and without membrane staining.

We did not find any significant association between NIS expression in the membrane and age, tumor size, tumor capsule, multifocality, lymphocytic infiltration, vascular invasion, lymph node metastases, tumor margins, distant metastases, staging, *BRAF*, *NRAS* and *TERT*p status, additional treatments, disease-free status at one year, disease-free status at the end of follow-up or disease-specific survival in the DTC group. When we analyzed NIS expression between WT PTCs and those harboring any of the studied mutations, we verified that NIS-positive expression was significantly more frequent in WT PTCs (*P* = 0.01) ([Table 2](#tbl2){ref-type="table"}). The number of RAI therapies, as well as the cumulative dose of RAI, did not differ significantly between patients with or without NIS expression in the basolateral membrane of primary tumor's cells. Table 2Associations between NIS expression and clinicopathological and molecular features in PTCs.**NIS immunoexpression*P* value**NegativePositiveGenetic background *n* = 118 WT45 (41.3%)8 (88.9%) Mutated^\#^64 (58.7%)1 (11.1%)0.011[^2]

The thorough analysis of the few cases with membrane staining (*n* = 12) revealed that all but one carcinoma were wild type for the studied mutations (*NRAS*, *BRAF* or *TERT*p). These cases presented variable outcomes i.e. presence of distant metastases, number of RAI therapies, cumulative dose of RAI, the need of additional treatments, disease-free status and death (disease caused), that are apparently unrelated with the presence of NIS membrane expression ([Table 3](#tbl3){ref-type="table"}). Table 3Clinicopathological and molecular data of cases presenting NIS membrane staining.**Diagnosis*BRAF**NRAS**TERT*pLymph node metastasesDistant metastasesNumber of ^131^I therapiesCumulative dose** (mCi)**Aditional treatmentsOne year DFS**\***DFS\*^,\#^Deaths**Case 1cPTCWTWTWTNoBone3457.5NoNoNoNoCase 2cPTCWTWTWTNoNo163NoYesYesNoCase 3cPTCWTWTWTYesNo34592 surgeriesNoNoNoCase 4fvPTCWTWTWTYesNo137NoYesYesNoCase 5fvPTCWTWTWTNoNo2382NoNoNoNoCase 6PDTCWTWTWTNoLung + bone57982 surgeriesYesNoNoCase 7cPTCWTWT124G\>AYesNo4527U/INoNoNoCase 8sclPTCWTWTWTYesNo3400U/INoNoNoCase 9FTCWTWTWTNoNo1102U/IU/IYesNoCase 10cPTCWTWTWTYesU/IU/IU/IU/IU/IU/IU/ICase 11fvPTCWTWTWTU/IU/IU/IU/IU/IU/IU/IU/ICase 12cPTCWTWTWTYesU/IU/IU/IU/IU/IU/IU/I[^3][^4]

Discussion
==========

In this work, we tried to clarify the impact of NIS expression (mRNA and protein) on thyroid tumors' aggressiveness and therapy success and, as a result of the above, the putative prognostic significance of *SLC5A5* mRNA and NIS protein expression. Moreover, we also addressed the impact of the genetic background of the tumor on *SLC5A5* and NIS expression as well as its targeting to the basolateral cell membrane.

We found that *SLC5A5* expression was always lower in tumors than in normal adjacent counterparts as reported by other groups ([@bib6], [@bib7], [@bib37]). We observed a significantly lower *SLC5A5* expression in male gender patients, and in cases with vascular invasion, as well as a tendency to lower *SLC5A5* expression in cases with extrathyroidal extension, but no differences were found in cases with and without lymph node metastases ([Table 1](#tbl1){ref-type="table"}). When we compare the results from our series to those from TCGA data, we confirmed that tumors express significantly less *SLC5A5* compared to normal adjacent tissue, that *SLC5A5* was not differently expressed in the presence or absence of lymph node metastases (at the time of diagnosis) and a significant lower *SLC5A5* expression was found in tumors with extrathyroidal extension (moderate/advanced) compared to those without extrathyroidal extension ([Fig. 2D](#fig2){ref-type="fig"}). However, the differential expression of *SLC5A5* between genders was not confirmed ([Fig. 2B](#fig2){ref-type="fig"}). Unfortunately, in TCGA database, there was no information about vascular invasion, so we could not validate this result in this large series.

The significantly lower *SLC5A5* expression in cases presenting vascular invasion and extrathyroidal extension suggests that a decreased *SLC5A5* expression may be associated to an aggressive tumor behavior and thus may help to characterize patients at risk for poor therapy response. Further analysis of TCGA data demonstrated that *SLC5A5* expression is significantly lower in cases that had locoregional recurrences and/or distant metastases ([Fig. 2E](#fig2){ref-type="fig"}). Given the high prognostic impact of recurrences and distant metastases ([@bib38]), these results suggest that a lower expression of *SLC5A5* in thyroid primary tumor seems to be associated with features of higher aggressiveness of the primary tumor and also with a worse prognosis and with poor response to therapy. Two groups reported that *SLC5A5* was significantly less expressed in DTCs larger than 2 cm and PTCs larger than 1 cm (in comparison to ≤2 cm and \<1 cm, respectively) ([@bib1], [@bib39]), TCGA results corroborated the literature by showing that larger PTCs (\>2 cm) expressed significantly less *SLC5A5* compared to those with ≤2 cm. Since larger tumors are associated with higher recurrence rates and worse prognosis ([@bib40], [@bib41]), the significantly lower *SLC5A5* expression in tumors larger than 2 cm may be considered as an additional fact linking lower *SLC5A5* mRNA expression with higher tumor aggressiveness. Nevertheless, we must interpret this information carefully: larger tumors may present higher levels of necrosis/fibrosis and also additional non-carcinomatous tissue as part of the nodule, which may contribute to a lower *SLC5A*5 expression. In our series, we did not include microcarcinomas, so the group of tumors with ≤2 cm was very small, precluding any meaningful analysis (data not shown).

Previous studies reported a lower *SLC5A5* expression in cases harboring *BRAF*V600E, and there is experimental evidence showing that *BRAF*V600E can impair *SLC5A5* expression ([@bib1], [@bib19], [@bib27], [@bib39]), nevertheless the impact of other relevant mutations found in thyroid tumors on *SLC5A5* expression remained unknown. In our series, *SLC5A5* expression was lower but did not reach statistical significance in the *BRAF*V600E PTC compared to that of *BRAF* wild-type group. The lack of significance in our series may be due to differences in size and composition of the series, since the above mentioned studies addressing *SLC5A5* expression and *BRAF* V600E ([@bib1], [@bib19], [@bib27], [@bib39]) used larger series of PTC.

When we compared *SLC5A5* expression (retrieved from TCGA database) between PTCs harboring different mutations (*BRAF*V600E, *TERT*p and *RAS*) and WT PTCs, we observed that independently of the mutation, *SLC5A5* expression was always significantly lower compared to WT PTCs. Moreover, we also observed that *RAS* mutation was the one with lower impact on *SLC5A5* expression. PTCs with *RAS* mutation displayed significantly higher levels of *SLC5A5* compared to *BRAF*V600E and *BRAF* + *TERT*p-mutated PTCs. In fact, it has been previously reported that a distinct profile of expression of genes involved in thyroid hormone biosynthesis (being *SLC5A5* one of these genes) between *BRAF*V600E and *RAS*-driven PTCs, with *RAS*-like PTCs having relatively high thyroid differentiation score ([@bib30]).

Our results on the immunohistochemical NIS expression in normal thyroid and Graves' disease (an autoimmune condition known to express high levels of NIS) ([@bib42]) were in accordance to data previously reported ([@bib10], [@bib12], [@bib14], [@bib17], [@bib21]), i.e., focal membrane expression of NIS in normal thyroid gland and a strong and widespread membrane NIS expression in Graves' disease. The great difference observed in NIS expression between normal thyroid and in Graves' disease may be considered as an example of how TSH is able to regulate NIS expression and the targeting to the membrane. Regarding carcinomas, we observed that the majority (71.6%) displayed NIS immunostaining, which is in accordance to the literature ([@bib13], [@bib14], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23]) ([Table 4](#tbl4){ref-type="table"}), but only a minority presented NIS in the basolateral membrane of tumor cells (5.7%). If one compares the percentage of cases with NIS plasma membrane staining, there are large differences between studies ([Table 4](#tbl4){ref-type="table"}). Such differences may be due to the variable size of the series and to differences in the antibodies used to perform the IHC (almost every study uses its own antibody, [Table 4](#tbl4){ref-type="table"}). In fact, one study compared NIS immunostaining using two different antibodies in a large series of thyroid carcinomas and observed some differences in the percentage of positive cells ([@bib29]). To be sure that we were not missing any signal, we performed the IHC for NIS with TSA signal amplification in a subset of carcinomas with different immunostaining patterns and observed a complete vanish of intracytoplasmic staining and an amplification of the membrane staining. These results, like those from Peyrottes and coworkers ([@bib21]) rise some questions about the real significance of NIS intracytoplasmic staining, so we decided to perform our analysis considering positive only the cases with membrane staining. Table 4Bibliographic revision and present results of NIS protein evaluation by IHC in thyroid carcinomas.**ReferenceNo. of carcinomasAnti-NIS antibodies used in the studyNegative cases** (%)**Positive cases** (%)\***Cases with membrane staining** (%)\*\*([@bib26])4 DTCsProduced by authors([@bib10])14 DTCsProduced by authorsDescriptive studies([@bib11])12 PTCsProduced by authors([@bib12])9 DTCsProduced by authors([@bib13])60 DTCsClone FP-1326.773.3N/A([@bib14])57 (53 DTCs; 2 ATC; 2 MTC)Produced by authors29.870.215.8([@bib15])67 DTCsDonated by Dr SM Jhiang of Ohio State University, USA67.232.8N/A([@bib17])90 (87 DTCs; 3 ATC)Produced by authors22.577.5Some([@bib24])67 PTCsPohlenz *et al*. (2000)N/ASome([@bib18])17 PTCsClone Ab-1010058.8([@bib19])40 PTCsBrahms Diagnostica GmbH, Berlin, Germany010052.5([@bib20])29 (25 DTCs; 4 ATC)Clone FP5A37.562.5N/A([@bib21])47 (42 DTCs; 5MTC)Clones 39S, Ab-1 and FP5A49510([@bib25])50 PTCsTazebay *et al*. (2000)N/A8([@bib22])32 DTCsZhongshan Goldbridge Biotechnology, Beijin China010018.8([@bib1])^\#^265 DTCsClone FP5A881212([@bib29])^\#^380 (283 DTCs; 97 ATCs)Donated by N. Morgenthaler (Brahms Diagnostics, Henningsdorf, Germany)87.412.612.6([@bib23])370 PTCsClone SPM18632.767.30.8(present study)211 (199 DTCs; 12 PDTCs)Clone FP5A28.471.65.7[^5][^6]

The presence of NIS in the basolateral membrane of thyroid primary carcinomas did not associate with clinicopathological features, response to therapy or prognosis. If we look to the treatment of thyroid carcinoma (surgery followed by RAI ablation), only the remnants, metastases and eventually the recurrences are subjected to RAI. Prior to RAI ablation patients are subjected to TSH stimulation, either by withdrawal of thyroid hormones or by the administration of recombinant TSH ([@bib2]). Since TSH has a major role in NIS expression and targeting to the membrane ([@bib43]), we can hypothesize that levels of membrane NIS in stimulated recurrences and metastases may be different from those in non-stimulated primary tumors because they may reflect two different biological conditions. It seems pertinent that further studies of NIS expression should be performed in recurrences and/or remaining thyroid tissues rather than in the primary tumors. In fact, one study addressed NIS expression in nontumoral thyroid tissue and reported a significant association between lower NIS expression and delayed structural response ([@bib3]). Even though the nontumoral tissue used in this study was obtained at the time of surgery (normal TSH levels), this might corroborate our hypothesis. Altogether, this information may help to explain why NIS expression in the primary tumor does not predict RAI therapy success and/or prognosis.

Another interesting finding of our study was the observation that the cases with NIS membrane staining were predominantly wild type for the analyzed mutations (*NRAS*, *BRAF* and *TERT*p) ([Table 3](#tbl3){ref-type="table"}). Although this membrane expression was not associated with any outcome (clinicopathological features or prognosis), it is tempting to advance that the genetic background of tumors influence NIS targeting to the membrane. There are *in vitro* evidence that *BRAF*V600E mutation affects NIS targeting to the membrane ([@bib24]), but the impact of the other mutations (*NRAS* and *TERT*p) remains unknown.

In summary, the absence of *BRAF* and *NRAS* mutations in every carcinoma displaying NIS membrane staining at immunohistochemistry supports the assumption that the genetic background of tumors may be of major importance to *SLC5A5* expression as well as to NIS targeting to the basolateral membrane. On the other hand, NIS immunohistochemical expression did not predict tumor behavior, therapy response or outcome. Moreover, *SLC5A5* mRNA expression was significantly lower in mutated PTCs and a lower *SLC5A5* mRNA expression was associated with tumor aggressiveness and worse prognosis. Thus, the study of *SLC5A5* mRNA expression is much more informative compared to NIS expression evaluated by IHC.
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[^1]: \*PTC only.

[^2]: ^\#^*BRAF, NRAS* or *TERT*p mutations.

[^3]: \*DFS disease-free survival; ^\#^at the end of follow-up.

[^4]: sclPTC, sclerosing variant of PTC; U/I, unavailable information.

[^5]: \*Percentage of positive cases (independently of the cellular location); \*\*percentage of cases with NIS membrane staining with or without simultaneous cytoplasmic staining; ^\#^these specific studies only considered positive cases with membrane staining.

[^6]: ATC, anaplastic thyroid carcinoma; MTC, medullary thyroid carcinoma; N/A, not addressed; PDTC, poorly differentiated thyroid carcinoma.
